ArticleEndocrine2020
Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans.
Article in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The relationship between low prolactin and type 2 diabetes.Reviews in endocrine & metabolic disorders · 2024Pooled it
- Ketogenic Diet Benefits to Weight Loss, Glycemic Control, and Lipid Profiles in Overweight Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trails.International journal of environmental research and public health · 2022Pooled it
- Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis.Nutrition & diabetes · 2020Pooled it
- Cardiometabolic effects of sequential prolactin states in dopamine agonist-treated prolactinoma patients: a retrospective longitudinal study.Pituitary · 2026Observational
- The effect of hypoprolactinemia on cardiometabolic effects of rosuvastatin in men: A matched Cohort Pilot Study.Pituitary · 2026Article
- Lower prolactin levels are associated with histological severity of metabolic dysfunction-associated steatotic liver disease.BMC endocrine disorders · 2026Article
- Endocan levels in patients with hyperprolactinemia.BMC endocrine disorders · 2025Article
- The impact of hypoprolactinemia on cardiometabolic effects of metformin in young women: a pilot prospective cohort study.Journal of endocrinological investigation · 2025Article
- Dietary supplementation with wholemeal bee powder (Apis mellifera) effect on improving metabolic parameters and modulating lipogenesis genes in diet-induced obese mice.Molecular biology reports · 2025Article
- Abnormally Increased Prolactin Levels in Women with Polycystic Ovarian Syndrome Are Associated with Risk of Obesity, Insulin Resistance and Prediabetes.International journal of molecular sciences · 2025Article
- Mildly elevated serum prolactin level may be a protective factor for preventing thickening of the carotid intima-media in patients with type 2 diabetes mellitus.Endocrine connections · 2025Article
- Scientific Progress in Polycystic Ovary Syndrome: Little by Little.Journal of clinical medicine · 2025Article
- Recent advances in anterior pituitary hormones and metabolic-associated fatty liver disease.Frontiers in endocrinology · 2025Review
- Article
- Changes in Prolactin and Insulin Resistance in PCOS Patients Undergoing Metformin Treatment: A Retrospective Study.Journal of clinical medicine · 2024Article
- Cardiometabolic effects of hypoprolactinemia.Reviews in endocrine & metabolic disorders · 2024Review
- The homeo-FIT-prolactin hypothesis: the role of prolactin in metabolic homeostasis - association or causality?Reviews in endocrine & metabolic disorders · 2024Review
- The molecular basis of hypoprolactinaemia.Reviews in endocrine & metabolic disorders · 2024Review
- What do we know about abnormally low prolactin levels in polycystic ovary syndrome? A narrative review.Reviews in endocrine & metabolic disorders · 2024Review
- The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double-edge sword.Journal of cellular and molecular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLow prolactin (PRL) serum levels are associated with glucose intolerance and type 2 diabetes in adults, and with metabolic syndrome and obesity in children. In obese rodents, PRL treatment promotes insulin sensitivity by maintaining adipose tissue fitness, and lack of PRL signaling exacerbates obesity-derived metabolic alterations. Since adipose tissue dysfunction is a key factor triggering metabolic alterations, we evaluated whether PRL serum levels are associated with adipocyte hypertrophy (a marker of adipose tissue dysfunction), insulin resistance, and metabolic syndrome in lean, overweight, and obese adult men and women.
methodsSamples of serum and adipose tissue from 40 subjects were obtained to evaluate insulin resistance index (homeostasis model assessment of insulin resistance (HOMA-IR)), signs of metabolic syndrome (glucose levels, high-density lipoproteins, triglycerides, blood pressure, and waist circumference), as well as adipocyte size and gene expression in fat.
resultsLower PRL serum levels are associated with adipocyte hypertrophy, in visceral but not in subcutaneous fat, and with a higher HOMA-IR. Furthermore, low systemic PRL levels together with high waist circumference predict an elevated HOMA-IR whereas low serum PRL values in combination with high blood glucose predicts visceral adipocyte hypertrophy. In agreement, visceral fat from insulin resistant subjects shows reduced expression of prolactin receptor. However, there is no association between PRL levels and obesity or signs of metabolic syndrome.
conclusionsOur results support that low levels of PRL are markers of visceral fat dysfunction and insulin resistance, and suggest the potential therapeutic value of medications elevating PRL levels to help maintain metabolic homeostasis.
Indexed as
Identifiers
31919769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.